Adma Biologics (ADMA) EBIAT (2016 - 2025)
Adma Biologics' EBIAT history spans 13 years, with the latest figure at $49.4 million for Q4 2025.
- For Q4 2025, EBIAT fell 55.87% year-over-year to $49.4 million; the TTM value through Dec 2025 reached $146.9 million, down 25.67%, while the annual FY2025 figure was $146.9 million, 25.67% down from the prior year.
- EBIAT reached $49.4 million in Q4 2025 per ADMA's latest filing, up from $36.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $111.9 million in Q4 2024 to a low of -$25.0 million in Q1 2022.
- Average EBIAT over 5 years is $8.9 million, with a median of -$6.6 million recorded in 2023.
- Peak YoY movement for EBIAT: soared 1299.96% in 2024, then crashed 55.87% in 2025.
- A 5-year view of EBIAT shows it stood at -$16.6 million in 2021, then increased by 26.54% to -$12.2 million in 2022, then plummeted by 44.26% to -$17.6 million in 2023, then soared by 734.15% to $111.9 million in 2024, then plummeted by 55.87% to $49.4 million in 2025.
- Per Business Quant, the three most recent readings for ADMA's EBIAT are $49.4 million (Q4 2025), $36.4 million (Q3 2025), and $34.2 million (Q2 2025).